Synthesis and Pharmacological Activity of 2-(Diethylamino)Ethyl 9-Hydroxy-9H-Fluorene-9-Carboxylate Hydrochloride
- Authors: Khnychenko L.K.1, Yakovleva E.E.1
- 
							Affiliations: 
							- Institute of Experimental Medicine
 
- Issue: Vol 53, No 3 (2019)
- Pages: 216-219
- Section: Article
- URL: https://ogarev-online.ru/0091-150X/article/view/245698
- DOI: https://doi.org/10.1007/s11094-019-01982-5
- ID: 245698
Cite item
Abstract
New fluorenecarboxylic acid derivatives (structural analogs of amizil) were synthesized. A compound with low toxicity (LD50 = 45 ± 9.9 mg/kg) and antidepressant and antianxiety effects was identified. The central and peripheral muscarinic anticholinergic properties of 2-dimethylaminoethyl 9-hydroxyfluorene-9-carboxylate were studied using an arecoline tremor model. Apharmacological analysis showed that the new amizil structural analog exhibited pronounced central muscarinic anticholinergic activity and did not possess peripheral muscarinic anticholinergic effects. The advantages of the tested compound over amizil, amitriptyline that is widely used in the clinic, and the benzodiazepine tranquilizer diazepam were discussed. The results indicated that 2-diethylaminoethyl 9-hydroxyfluorene-9-carboxylate was promising for further development for the treatment of depressive and anxiety disorders.
About the authors
L. K. Khnychenko
Institute of Experimental Medicine
							Author for correspondence.
							Email: ludmila.konst83@mail.ru
				                					                																			                												                	Russian Federation, 							St. Petersburg, 197375						
E. E. Yakovleva
Institute of Experimental Medicine
														Email: ludmila.konst83@mail.ru
				                					                																			                												                	Russian Federation, 							St. Petersburg, 197375						
Supplementary files
 
				
			 
					 
						 
						 
						 
						 
				 
  
  
  
  
  Email this article
			Email this article  Open Access
		                                Open Access Access granted
						Access granted Subscription Access
		                                		                                        Subscription Access
		                                					